Phase 2 Bladder Cancer Trial, Recruiting NCT07122414 Sponsor: Suzhou Forlong Biotechnology Co., Ltd Condition: Bladder Cancer
Back to Bladder Cancer

Phase 2 Bladder Cancer Trial, Recruiting

NCT07122414
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a specific type of bladder cancer (called high-grade transitional cell carcinoma) that has not grown into the bladder muscle, confirmed by a tissue sample
  • Your bladder cancer has not responded to BCG treatment (a common bladder cancer therapy), and this has been confirmed by tissue testing
  • After surgical removal of tumors (a procedure called TURBT), there is no remaining removable disease — though some surface-level cancer cells in the lining may still be present
  • You are either unwilling to have your bladder surgically removed, or your doctor has determined that surgery is not suitable for you
  • Your general health and activity level fall within an acceptable range (confirm with trial site)
  • Your doctor expects you to live for at least 2 more years
  • Your major organs (such as kidneys, liver, and heart) are functioning well enough to participate
  • You are willing to give written consent and agree to follow all trial procedures and check-ups

Who may not be able to join:

  • You have previously received certain immune-boosting therapies involving IL-2 or IL-15 (specific drug types — confirm with trial site)
  • You received significant pelvic radiation therapy within the past 2 years
  • You received any systemic (whole-body) treatment for your bladder cancer within the past 4 weeks
  • You received any treatment directly into the bladder (intravesical therapy) within the past 4 weeks
  • You had bladder surgery (such as TURBT) within the past 2 weeks
  • You have a known allergy to the trial drug or similar types of treatments, or to BCG (confirm with trial site)
  • You have been taking immune-suppressing medications at significant doses within the past 4 weeks (some low-dose exceptions may apply — confirm with trial site)
  • You have previously had an organ transplant or bone marrow/stem cell transplant from another person
  • You received a live virus vaccine within the past 4 weeks
  • You previously had a severe or treatment-stopping immune-related side effect from an immunotherapy drug (some exceptions may apply — confirm with trial site)
  • You have unresolved serious side effects from previous cancer treatments that have not sufficiently improved
  • You have a history of bladder cancer that has grown into the muscle or spread to other parts of the body
  • You have had tumors in your upper urinary tract (such as the kidneys or ureters) or in the urethral area near the prostate
  • You have a known condition where urine flows backward from the bladder to the kidneys, or there is evidence of a hole in your bladder
  • You currently have an active urinary tract infection
  • You had to stop BCG treatment in the past due to serious reactions such as blood poisoning or serious infection
  • You have complications from bladder surgery that would prevent treatment being placed directly into the bladder
  • You produce an unusually large amount of urine each day (more than 4,000 mL in 24 hours)
  • You have been diagnosed with another cancer within the past 2 years that is still active or required treatment
  • You have an active autoimmune disease that requires immune-suppressing medication
  • You have a history of serious lung damage or lung toxicity
  • You have had active tuberculosis (TB) in the lungs within the past year, or a past TB infection that was not fully treated
  • You have uncontrolled fluid build-up around your lungs, heart, or abdomen that requires frequent draining
  • You have a significant history of serious heart disease
  • You had major surgery within the past 4 weeks
  • You have had a serious infection within the past 4 weeks
  • You have ever had confirmed active Hepatitis B, Hepatitis C, HIV, or active tuberculosis
  • You are currently pregnant or breastfeeding
  • You have a known or suspected substance misuse problem (certain exceptions for medically prescribed medications may apply — confirm with trial site)
  • Your doctor determines there is any other reason you would not be suitable for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-18101882657

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Suzhou Forlong Biotechnology Co., Ltd
Registry
ClinicalTrials.gov
Start date
16 August 2024
Est. completion
10 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

MTD; RP2D; Safety and tolerability; Complete Response; Disease-Free Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov